Dr. Gurmukh Singh to Lead July 29th Workshop on “Pathogenicity of Monoclonal Immunoglobulin Light Chains”
Helena Laboratories, in keeping with its commitment to advancing clinical education, will host a workshop on free light chain analysis led by Gurmukh Singh, MD, PhD, MBA, Shepeard Chair in Clinical Pathology and Chief of Clinical Pathology at Augusta University Medical College of Georgia. The session will be moderated by Dr. Robert Galen, Professor Emeritus, College of Public Health, University of Georgia. This industry-sponsored workshop, held in conjunction with the ADLM 2026 Clinical Lab Expo, will take place on Wednesday, July 29th at 6 pm at the Hilton Anaheim, Room California A.
The workshop will focus on critical analysis of free light chains in multiple myeloma. Most often in multiple myeloma, malignant plasma cells give rise to monoclonal light chains along with intact monoclonal immunoglobulins. But some multiple myeloma lesions may produce light chains only. In both types of myelomas, higher levels of free monoclonal immunoglobulins are associated with renal damage and a worse prognosis reflected by two-year shorter survival. In intact immunoglobulin myelomas, light chain predominant myelomas are diagnosed when the level of monoclonal light chains per gram of intact immunoglobulin are higher than 67.0 mg of light chain per gram of monoclonal immunoglobulins for kappa chain associated lesions. The corresponding figure for lambda chain associated myelomas is 43.5.
Attendees can expect to:
- Understand the diagnostic criteria for light chain predominant multiple myeloma.
- Recognize the differences in the light chains and specific diagnostic criteria for kappa and lambda light chain associated lesions.
- Appreciate the pathogenicity of monoclonal light chains being a dominant cause of renal failure and shorter survival.
Dr. Singh brings over four decades of clinical, academic, and research experience and expertise in immunopathology, anatomic and clinical pathology. He is keen to continue his clinical research to further expand treatment options and care information for multiple myeloma patients.
The workshop is open to clinical laboratory professionals. Seating is available on a first-come, first-serve basis.